AR128065A1 - Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares - Google Patents
Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u ocularesInfo
- Publication number
- AR128065A1 AR128065A1 ARP220103548A ARP220103548A AR128065A1 AR 128065 A1 AR128065 A1 AR 128065A1 AR P220103548 A ARP220103548 A AR P220103548A AR P220103548 A ARP220103548 A AR P220103548A AR 128065 A1 AR128065 A1 AR 128065A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- antibodies
- antibody
- binding fragment
- binding fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 6
- 208000030533 eye disease Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000016918 Complement C3 Human genes 0.000 abstract 1
- 108010028780 Complement C3 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Anticuerpos y fragmentos de estos que se dirigen al complemento C3. Más específicamente, anticuerpos anti-C3 y métodos de uso para el tratamiento de diversas enfermedades o trastornos. Reivindicación 34: Una composición farmacéutica caracterizada porque comprende un anticuerpo o un fragmento de unión al antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 24 y un portador aceptable desde el punto de vista farmacéutico. Reivindicación 35: Una composición farmacéutica caracterizada porque comprende un polinucleótido o polinucleótidos que codifican un anticuerpo o un fragmento de unión al antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 24 y un portador aceptable desde el punto de vista farmacéutico. Reivindicación 38: Un polinucleótido o polinucleótidos aislados caracterizado porque codifican un anticuerpo o un fragmento de unión al antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 24. Reivindicación 42: Un método para producir un anticuerpo anti-C3 o un fragmento de unión al antígeno de este caracterizado porque comprende: a. obtener una célula huésped de acuerdo con la reivindicación 41 y b. cultivar la célula huésped.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163292513P | 2021-12-22 | 2021-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128065A1 true AR128065A1 (es) | 2024-03-20 |
Family
ID=84981666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103548A AR128065A1 (es) | 2021-12-22 | 2022-12-21 | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230257455A1 (es) |
AR (1) | AR128065A1 (es) |
AU (1) | AU2022420788A1 (es) |
CA (1) | CA3239286A1 (es) |
CO (1) | CO2024007361A2 (es) |
TW (1) | TW202342515A (es) |
WO (1) | WO2023118312A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024086555A1 (en) * | 2022-10-17 | 2024-04-25 | Ngm Biopharmaceuticals, Inc. | Uses of anti-c3 antibodies |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
CN110249053A (zh) | 2016-10-17 | 2019-09-17 | 阿佩利斯制药有限公司 | 用于c3抑制的组合疗法 |
CA3093356A1 (en) | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
CN111171148B (zh) * | 2020-02-11 | 2021-07-20 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c3分子的人源化单链抗体及其应用 |
WO2021226442A2 (en) * | 2020-05-08 | 2021-11-11 | Ngm Biopharmaceuticals, Inc. | Therapeutic uses of c3-binding agents |
-
2022
- 2022-12-21 AU AU2022420788A patent/AU2022420788A1/en active Pending
- 2022-12-21 US US18/069,712 patent/US20230257455A1/en active Pending
- 2022-12-21 AR ARP220103548A patent/AR128065A1/es unknown
- 2022-12-21 WO PCT/EP2022/087260 patent/WO2023118312A1/en active Application Filing
- 2022-12-21 CA CA3239286A patent/CA3239286A1/en active Pending
- 2022-12-21 TW TW111149100A patent/TW202342515A/zh unknown
-
2024
- 2024-06-12 CO CONC2024/0007361A patent/CO2024007361A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202342515A (zh) | 2023-11-01 |
US20230257455A1 (en) | 2023-08-17 |
WO2023118312A1 (en) | 2023-06-29 |
AU2022420788A1 (en) | 2024-05-16 |
CA3239286A1 (en) | 2023-06-29 |
CO2024007361A2 (es) | 2024-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
CL2018002991A1 (es) | Formulaciones de un inhibidor de lsd1. | |
CL2021001162A1 (es) | Proteínas de fusión fc il-22 y métodos de uso. (divisional de solicitud 202001944) | |
PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
AR128065A1 (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
CO2022002001A2 (es) | Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr | |
AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
EA202190807A1 (ru) | Антитела к синуклеину | |
EA202193038A1 (ru) | Антитела против sema3a и их применения для лечения заболеваний глаз | |
EA202092459A1 (ru) | Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают | |
WO2020132658A3 (en) | Tubulysins and protein-tubulysin conjugates | |
MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
BR112023019546A2 (pt) | Anticorpos anti-tau e usos dos mesmos | |
AR108790A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria | |
BR112023002455A2 (pt) | Anticorpos fgfr3 e métodos de uso | |
MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
BR112022004475A2 (pt) | Proteínas de fusão nkg2d e usos das mesmas | |
AR119496A1 (es) | Proteínas de unión a antígeno anti-il13 | |
EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
MX2020013243A (es) | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. |